Research programme: macrocyclinc compounds: Cyclenium Pharma/Ono
Latest Information Update: 13 Jun 2023
At a glance
- Originator Cyclenium Pharma; Ono Pharmaceutical
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 06 Jun 2023 Cyclenium Pharma has been acquired by SpiroChem
- 28 Jan 2022 No recent reports of development identified for research development in Unspecified in Canada
- 28 Jan 2022 No recent reports of development identified for research development in Unspecified in Japan